Abstract 1536P
Background
HER-Vaxx is a B cell peptide-based anti-Her2 vaccine (IMU-131) comprising B cell epitopes located within trastuzumab’s binding site. In the phase Ib HERIZON trial (NCT02795988), HER-Vaxx has been shown to be safe and to prolong progression-free survival in patients with Her2-overexpressing gastric/gastro-oesophageal junction cancer (GC). The present randomized phase II open-label, multicentre study, compared two different doses of HER-Vaxx plus chemotherapy vs chemotherapy alone and aimed to evaluate antibody and clinical responses in patients with advanced or metastatic Her2-overexpressing GC naïve to Her2 therapy.
Methods
Patients were randomized to chemotherapy alone (n=17) or HER-Vaxx (50μg dose, n=19; 100μg, n=7) plus chemotherapy. In both vaccination groups, the patients received the vaccine at days 0, 14, 35, and 77 followed by q. 63 days until disease progression. Chemotherapy consisted of oxaliplatin plus capecitabine and was started at day 0, repeated q. 21 days for a maximum of 6 cycles. Specific anti-Her2 IgG antibody levels in the patient’s sera were evaluated by ELISA and clinical responses were assessed by RECIST 1.1 criteria.
Results
Evaluation of the vaccine’s two doses showed no difference in the induced Her2-specific IgG and IgG1 antibody responses, which, compared to patients from the chemotherapy-only group, were both significantly elevated (P<0.001) at all time points after 3 or more vaccinations. No further reduction of tumour diameters was observed with the vaccine’s higher dose, and the induced Her2-specific antibodies following vaccination with either dose significantly correlated with the anti-tumour effect (IgG, P=0.001; IgG1, P=0.016). Moreover, the vaccine-induced IgG antibodies had the capacity to inhibit intracellular phosphorylation of Her2 and exhibited binding to the gastric cancer cell line N87 overexpressing Her2.
Conclusions
Vaccination with HER-Vaxx in patients with Her2-overexpressing GC at doses of 50μg and 100μg led to an anti-tumour effect that correlated with anti-Her2 IgG antibody levels.
Clinical trial identification
NCT02795988.
Editorial acknowledgement
Legal entity responsible for the study
Imugene Limited.
Funding
Has not received any funding.
Disclosure
C. Zielinski: Other, Personal, Other, Consultancies and Speaker’s Honoraria: Athenex, MSD, AstraZeneca, Servier, Eli Lilly; Other, Personal, Other, Patents: Imugene Limited; Other, Institutional, Other: BMS, MSD, Pfizer, AstraZeneca, Merck KgAa, Amgen, Servier, Eli Lilly, Takeda, Daiichi Sankyo, Roche, Boehringer Ingelheim, Celgene, Halozyme. L.O. Chong: Financial Interests, Personal, Leadership Role: Imugene Limited. B. Nixon: Financial Interests, Personal, Stocks/Shares: Imugene Limited; Financial Interests, Personal, Full or part-time Employment: Imugene Limited; Financial Interests, Personal, Other, Spouse/Financial dependent: Imugene Limited. S. Yavrom, N. Ede: Financial Interests, Personal, Full or part-time Employment: Imugene Limited. U. Wiedermann: Other, Personal, Other, CSO of Imugene until September 2018; Patents: Imugene Limited; Other, Institutional, Other, Funding to the Institute: GSK, Pfizer, Themis. All other authors have declared no conflicts of interest.
Resources from the same session
1543P - Clinical study of camrelizumab combined with docetaxel and carboplatin in neoadjuvant treatment of locally advanced oesophageal squamous cell carcinoma
Presenter: Rui Wang
Session: Poster session 21
1544P - Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of advanced gastric/gastroesophageal junction cancer: A phase II clinical trial
Presenter: Xin fang Hou
Session: Poster session 21
1545P - Phase II trial of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus
Presenter: Yuexiao Qi
Session: Poster session 21
1546P - Safety, efficacy, and biomarkers for ONO-4578 plus nivolumab in unresectable advanced or recurrent gastric or gastroesophageal cancer
Presenter: Hidekazu Hirano
Session: Poster session 21
1547P - SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer
Presenter: Chiaki Inagaki
Session: Poster session 21
1549P - A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial
Presenter: Hiroyuki Takeda
Session: Poster session 21
1551P - Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric cancer
Presenter: Choong-kun Lee
Session: Poster session 21
1552P - Clinical multi-omics analysis of gastric cancer (GC) in Europe (EU) and Latin America (LatAm): The LEGACy project
Presenter: Tania Fleitas
Session: Poster session 21
1553P - Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: A randomized phase II proof-of-concept study
Presenter: Benthe Doeve
Session: Poster session 21